ArticleHuman vaccines & immunotherapeutics2025
Attitudes and acceptance of mRNA-based vaccine for neglected tropical diseases: A multi-country study in Asia.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants.Human vaccines & immunotherapeutics · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study seeks to investigate willingness to receive vaccination against NTDs using mRNA-based vaccines in various Asian countries, including China. Between June and December 2023, an anonymous cross-sectional survey was carried out in five countries. The survey assessed knowledge and attitudes regarding mRNA vaccines and their potential impact on vaccination acceptance. The majority indicated being somewhat willing (44.9%), 19.3% expressed extreme willingness. High knowledge scores (adjusted odds ratio [aOR] = 2.61, 95% confidence interval (CI): 2.31-2.96] were associated with higher willingness to receive mRNA-based NTD vaccines. Participants from Bangladesh recorded the highest proportion expressed willingness (51.4%), followed by China (15.9%). Vietnam (15.4%) and Malaysia (14.8%). Pakistan (11.0%) and India (11.3%) recorded lowest proportions of willingness. Understanding the mechanism of mRNA vaccines and awareness of the difference between mRNA vaccines and conventional ones are knowledge items that significantly predict acceptance. Concerns regarding potential unknown side effects associated with mRNA-based approaches, and the perception that traditional vaccine development methods are safer, negatively correlate with willingness. Conversely, the belief in the advantages of mRNA-based approaches, such as rapid development, heightened potency, and reduced cost, positively correlates with willingness. High overall knowledge and attitudes scores were associated with a higher willingness to receive vaccines. The younger age group and females demonstrated a greater vaccination acceptance. Overall, the study highlights both opportunities and challenges in promoting the uptake of mRNA-based vaccines against NTDs in Asia countries. The study provides insights into enhancing knowledge and fostering positive attitudes toward mRNA-based vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.